The content on this site is intended for healthcare professionals only
Prof Marco Cattaneo speaks to ecancer at the International Aspirin Foundation Scientific Conference 2019 in Rome about regulatory mechanisms of platelet activation and inhibition.
Prof Cattaneo explains the implications of the science behind platelet activation and inhibition for current treatment and future clinical research.
He concludes that, based on this research, it is likely that patients could be given lower doses of aspirin - meaning that they would experience fewer side effects.
Read more on the highlights from the 2019 International Aspirin Foundation Scientific Conference here.
Treatment management of favourable risk and very favourable risk patients
Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC
Geriatric interventions are beneficial in reducing treatment-related toxicity in older adults with cancer
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Reducing stigma for lung cancer and other smoking-related respiratory diseases
Supporting breast cancer patients in Vietnam
Choosing wisely in multiple myeloma
Intravesical IO using durvalumab shows promising results for patients with high risk NMIBC after BCG failure
